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Activating synthetic ligands for peroxisome proliferator-activated receptor gamma (PPARγ), such as pioglitazone, are commonly
used to treat persons with diabetes mellitus with improvement of insulin resistance. Several reports have clearly demonstrated that
PPARγ ligands could inhibit colorectal cancer cell growth and induce apoptosis. Meanwhile, aberrant crypt foci (ACF) have come
to be established as a biomarker of the risk of CRC in azoxymethane-treated mice and rats. In humans, ACF can be detected using
magnifying colonoscopy. Previously, CRC and adenoma were used as a target for chemopreventive agents, but it needs a long time
to evaluate, however, ACF can be a surrogate marker of CRC even for a brief period. In this clinical study, we investigated the
chemopreventive eﬀect of pioglitazone on the development of human ACF as a surrogate marker of CRC. Twenty-nine patients
were divided into two groups, 20 were in the endoscopically normal control group and 9 were in the pioglitazone (15mg/day)
group,andACFandadenomawereexaminedbeforeandafter1-monthtreatment.ThenumberofACFwassigniﬁcantlydecreased
(5.8 ± 1.1t o3 .3 ± 2.3) after 1 month of pioglitazone treatment, however, there was no signiﬁcant change in the number of
crypts/ACF or in the number and size of adenomas. Pioglitazone may have a clinical application as a cancer-preventive drug. This
investigation is just a pilot study, therefore, further clinical studies are needed to show that the PPARγ ligand may be a promising
candidate as a chemopreventive agent for colorectal carcinogenesis.
1.Introduction
Peroxisome proliferator-activated receptor gamma (PPARγ)
is expressed in adipose tissue and plays a central role in
adipocyte diﬀerentiation and insulin sensitivity. Activated
synthetic ligands for PPARγ are widely used as treatment for
type 2 diabetes mellitus (DM) in order to improve insulin
resistance. PPARγ is also overexpressed in many tumors [1–
5]. Several studies have reported that treatment of cancer
c e l l sw i t hP P A R γ ligands induces cell diﬀerentiation and
apoptosis, suggesting their potential application as chemo-
preventive agents against carcinogenesis [4, 6, 7]. Recent
studies have suggested that PPARγ has an inhibitory eﬀect
on cancer cell growth [8–10] and might inhibit cell growth
and induce apoptosis in adenocarcinomas [9, 11–13], as well
as aﬀect tubulin formation in vitro [14]. Initial eﬀorts have
f ocusedo nacti vatio nwithPP ARγ ligands,asthesehavebeen
shown to induce G1 cell cycle arrest in a variety of tumor cell
lines [15, 16]. Su et al. reported that PPARγ agonist inhibits
both initiation and progression of colon tumors in the
AOM-mouse model study [17]. We have reported previously
that PPARγ ligands suppress colonic epithelial cell turnover
and colon carcinogenesis through inhibition of the beta-
catenin/T cell factor pathway [18], and PPARγ ligands may
be potential chemopreventive agents in an azoxymethane-
induced colorectal carcinogenesis model and ApcMin/+ mice2 PPAR Research
Table 1: Clinical characteristics of study participants.
Treatment group
Control Pioglitazone P value
N2 0 9
Age (years) 63.9 ±10.06 1 .8 ±5.7 >. 05
Waist Circumference (cm) 96.5 ±13.69 1 .8 ±4.0 >. 05
BMI (kg/m2)2 4 .4 ±3.72 3 .4 ±3.1 >. 05
VFA (cm2) 130.0 ±61.2 146.1 ±40.9 >. 05
SFA (cm2) 151.5 ±60.5 141.8 ±53.5 >. 05
Data are expressed as mean ±SD.
model [19, 20]. Colorectal cancer (CRC) is potentially one
of the most preventable malignancies [21, 22]. However, the
results of clinical trials with PPARγ ligands in CRC have
shown only modest results. This implies that focusing on
PPARγ as a speciﬁc antitumoral target is not likely to be
successful, because PPARγ ligands are not an active agent
for the treatment of metastatic CRC or liposarcoma [23,
24]. Therefore, we have evaluated chemopreventive eﬀects
of PPARγ ligand on the formation of the human aberrant
crypt foci (ACF), which is an early stage of colorectal
carcinogenesis. ACF were ﬁrst discovered in mice treated
with azoxymethane [25] and have become established as
a biomarker of the risk of CRC in azoxymethane-treated
mice and rats [26]. In humans, ACF can be detected using
magnifyingcolonoscopy[27].Previously,CRCandadenoma
were used as a target for assessing the eﬃcacy of potential
chemopreventive agents; however, this model can only be
evaluated over a long period of time. In contrast, the
therapeutic eﬃcacy of a product can be evaluated in ACF
within a comparatively brief period. We report hire on the
results of a study that evaluated the chemopreventive eﬀect
of PPARγ ligand by using ACF as a surrogate marker of CRC.
2. Methods
2.1. Magnifying Colonoscopy for Identiﬁcation of ACF. Bowel
preparation for the colonoscopy was carried out using
polyethylene glycol solution. A Fujinon EC-490ZW5/M
colonoscope was used to perform the magnifying
colonoscopy (Fujinon Toshiba ES Systems Co., Ltd,
Tokyo, Japan). Total colonoscopy was performed before
imaging of rectal ACF. The exclusion criteria included:
presence of contraindications to colonoscopy; current or
past nonsteroidal anti-inﬂammatory drug use including
aspirin; or family history of CRC; or history of adenoma,
carcinoma, familial adenomatous polyposis, inﬂammatory
bowel disease, or radiation colitis. Subjects with a history
of colectomy, gastrectomy, or colorectal polypectomy were
also excluded. Colorectal adenomas were diagnosed from
pathological ﬁndings. Subsequently, 0.25% methylene
blue was applied to the mucosa of the lower rectal region
extending from the middle Houston’s valve to the dentate
line using spray catheter. ACF were described as lesions
consisting of large, thick crypts in methylene blue-stained
specimens of the colon (Figure 1). All ACF were recorded
photographically and evaluated by two independent
endoscopists who were unaware of the subjects’ clinical
histories. All the patients were divided into two groups, 20
were in the endoscopically normal control group and 9 were
in the pioglitazone (PPARγ ligand) group, (15mg/day); ACF
and adenoma were examined before and after 1 month of
treatment.
2.2. Measurement of the Visceral and Subcutaneous Fat Areas.
Body mass index (BMI) was calculated using the following
equation: body weight (kg)/[height (m)2]. Intra-abdominal
adipose tissue was assessed, as previously described, by
measuring the visceral fat area (VFA), subcutaneous fat area
(SFA),andwaistcircumferencefromcomputedtomographic
(CT) images at the level of the umbilicus. All CT scans
were carried out with the subjects in the supine position.
The borders of the intra-abdominal cavity were outlined on
the CT images, and the VFA was quantiﬁed using Fat Scan
software (N2 System Corporation, Kobe, Japan).
2.3. Statistical Analysis. Data are expressed as mean ±
standard deviation (SD), unless otherwise indicated. The
relationships between the number of ACF and relevant
covariates were examined by univariate regression analysis
and determined using the Stat View software (SAS Institute
Inc., Cary, NC, USA).
3. Results and Discussion
The clinical characteristics of the study participants are
shown in Table 1. There were no signiﬁcant diﬀerences
between the groups in terms of their mean age, waist
circumference,BMI,VFA,andSFA.Thetypicalcolonoscopic
features of ACF are shown in Figure 1. The number of ACF
was signiﬁcantly decreased after 1 month’s treatment with
PPARγ ligand compared with the controls who received no
treatment (P = .0226), however, there was no change in the
number of crypts/ACF (Table 2) and in ACF size (data not
shown). Similarly, after one month of treatment there was
no change in the number and size of adenoma (Table 2).
In the present study, pioglitazone treatment decreased
the number of ACF, however, the number of crypts/ACF
remained unchanged. These results suggest that pioglitazone
aﬀects ACF incidence rather than growth. The lack of change
in the number and size of the adenomas may have been
because the duration of pioglitazone administration was too
short to be eﬀective in this respect.
The limitations of this pilot study were its small size, its
short duration, and the absence of histological evaluation.
Additional research in a large number of subjects is needed
to elucidate the clinical eﬀect and beneﬁts of pioglitazone
in colorectal carcinogenesis. Chemopreventive trials, the use
of medications to prevent disease, have now been carried
out extensively in colorectal tumors, for example, supple-
mental ﬁbers [28], calcium supplementation [29], aspirin
[30], nonsteroidal anti-inﬂammatory drugs (NSAIDs), and
selectivecyclooxygenase(COX)-2inhibitors[31,32],haveall
been evaluated. Higher doses and longer durations of use ofPPAR Research 3
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Figure 1: Typical features of ACF on magnifying colonoscopy with methylene blue staining.
Table 2: Eﬀect of PPARγ ligand for human ACF and adenoma.
Pre-treatment Post-treatment P value
Number of ACF Control 5.4 ±4.05 .6 ±5.8 >. 05
Pioglitazone 5.8 ±1.13 .3 ±2.3 .0226
Number of Crypts/ACF Control 16.8 ±5.21 7 .8 ±6.4 >. 05
Pioglitazone 14.3 ±5.91 3 .6 ±6.7 >. 05
Number of adenoma Control 2.0 ±1.01 .8 ±0.8 >. 05
Pioglitazone 2.2 ±1.52 .3 ±2.1 >. 05
Mean size of adenoma (mm) Control 6.9 ±3.27 .0 ±3.3 >. 05
Pioglitazone 5.7 ±2.85 .8 ±2.8 >. 05
Location of maximum adenoma
Control Right side 8 8
Left side 12 12
Pioglitazone Right side 4 4
Left side 5 5
Data are expressed as mean ±SD.
NSAIDs and COX-2 inhibitors seem to be associated with
greater protection from CRC and adenoma. However, these
agents are associated with signiﬁcant cardiovascular events
and/or gastrointestinal harms [33]. Thus, the balanceof ben-
eﬁts to risk does not favor chemoprevention by these agents
in average-risk individuals. In conclusions, our preliminary
results from this pilot study suggest that pioglitazone may
have a preventive potential for human ACF and have a
goodsafetyproﬁleinthispatientpopulation.Furtherclinical
study is required to demonstrate that the PPARγ ligand may
be a promising candidate as a chemopreventive agent for
colorectal carcinogenesis.
Abbreviations
ACF: Aberrant crypt foci
CRC: Colorectal cancer
PPARγ: Peroxisome proliferator-activated receptor
gamma.
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